--- title: "Integrating talquetamab regimens in early relapsed/refractory multiple myeloma: implications and o" id: "nature-reviews-clinical-oncology-0-more-options-more-questions-in-the-management-of-early-relapsed-and-or" canonical_url: "https://medichelpline.com/clinical-feed/nature-reviews-clinical-oncology-0-more-options-more-questions-in-the-management-of-early-relapsed-and-or" content_type: "clinical_feed_article" specialty: "Oncology" source_name: "Nature Reviews Clinical Oncology" source_url: "https://www.nature.com/articles/s41571-026-01191-6" published_at: "2026-07-31T12:00:00.000Z" evidence_level: "Journal Feed" license: "CC-BY-NC-4.0 / Informational Use" --- # Integrating talquetamab regimens in early relapsed/refractory multiple myeloma: implications and o ## Provenance & Clinical Metadata - **Canonical URL:** https://medichelpline.com/clinical-feed/nature-reviews-clinical-oncology-0-more-options-more-questions-in-the-management-of-early-relapsed-and-or - **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md) - **Primary Source:** Nature Reviews Clinical Oncology - **Source URL:** [Original Journal Publication](https://www.nature.com/articles/s41571-026-01191-6) - **Published At:** 2026-07-31T12:00:00.000Z - **Evidence Rating:** Journal Feed ## Executive GIST (TL;DR) - The MonumenTAL-3 trial showed that the G-protein-coupled receptor class C group 5 member D (GPRC5D)-directed bispecific T cell engager **talquetamab**, when combined with either daratumumab or daratumumab–pomalidomide, produced significantly longer **progression-free survival** than daratumumab–pomalidomide–dexamethasone in patients with relapsed and/or refractory multiple myeloma after at least one prior therapy. - These results introduce a new therapeutic option for patients with early relapsed and/or refractory myeloma but create uncertainty about sequencing and combining talquetamab-based treatments with other T cell–redirecting therapies, notably those directed against B cell maturation antigen (**BCMA**). - The article situates MonumenTAL-3 in the context of recent and ongoing advances in myeloma immunotherapy, listing related studies and agents in the field, including BCMA-directed CAR T and bispecific agents (for example, cilta‑cel, ide‑cel, teclistamab), GPRC5D-targeted CAR T cells, and antibody–drug conjugates. - Several high-profile randomized and non-randomized trials relevant to relapsed/refractory myeloma are cited (for example, trials of belantamab mafodotin combinations, cilta‑cel, ide‑cel, teclistamab plus daratumumab, talquetamab combinations, and GPRC5D CAR T cells). - The source is a preview/News & Views–style piece and does not report detailed numerical outcomes or safety data from MonumenTAL-3 in the accessible text; specific efficacy, safety, and subgroup details were not reported in the source. - The findings prompt practical questions for clinicians about optimal patient selection, sequencing relative to **BCMA**-directed modalities, combination partner choices, and real-world applicability. - The article acknowledges the rapidly evolving therapeutic landscape in myeloma and highlights the need for integration strategies and comparative data to guide treatment decisions for patients who relapse early or are refractory to standard agents. ## Clinical Analysis & Structured Key Points ## Your privacy, your choice We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media, as well as to allow video information to be shared for both marketing, analytics and editorial purposes. By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection. See our [privacy policy](https://www.nature.com/info/privacy) for more information on the use of your personal data. Manage preferences for further information and to change your choices. Accept all cookies Reject optional cookies [Skip to main content](https://www.nature.com/articles/s41571-026-01191-6#content) Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. Advertisement [ ![Nature Reviews Clinical Oncology](https://media.springernature.com/full/nature-cms/uploads/product/nrclinonc/header-6cacb5c22900eb4634682a8eae5b788c.svg) ](https://www.nature.com/nrclinonc) * [ View all journals ](https://www.nature.com/siteindex) * [ Saved research ](https://www.nature.com/saved-research) * [ Search ](javascript:;) ## Search Search articles by subject, keyword or author Show results from All journals This journal Search [ Advanced search ](https://www.nature.com/search/advanced) ### Quick links * [Explore articles by subject](https://www.nature.com/subjects) * [Find a job](https://www.nature.com/naturecareers) * [Guide to authors](https://www.nature.com/authors/index.html) * [Editorial policies](https://www.nature.com/authors/editorial_policies/) * [Log in](https://idp.nature.com/auth/personal/springernature?redirect_uri=https://www.nature.com/articles/s41571-026-01191-6) * [ Content Explore content ](javascript:;) ## Explore content * [ Research articles ](https://www.nature.com/nrclinonc/research-articles) * [ Reviews & Analysis ](https://www.nature.com/nrclinonc/reviews-and-analysis) * [ News & Comment ](https://www.nature.com/nrclinonc/news-and-comment) * [ Current issue ](https://www.nature.com/nrclinonc/current-issue) * [ Collections ](https://www.nature.com/nrclinonc/collections) * [Follow us on Facebook ](https://www.facebook.com/NatureReviews) * [Follow us on X ](https://twitter.com/NatRevClinOncol) * [ Subscribe ](https://www.nature.com/nrclinonc/subscribe) * [Sign up for alerts ](https://journal-alerts.springernature.com/subscribe?journal_id=41571) * [ RSS feed ](https://www.nature.com/nrclinonc.rss) * [ About the journal ](javascript:;) ## About the journal * [ Aims & Scope ](https://www.nature.com/nrclinonc/aims) * [ Journal Information ](https://www.nature.com/nrclinonc/journal-information) * [ Editorial policies ](https://www.nature.com/nrclinonc/editorial-policies) * [ About the Editors ](https://www.nature.com/nrclinonc/editors) * [ Reviews Cross-Journal Editorial Team ](https://www.nature.com/nrclinonc/reviews-cross-journal-editorial-team) * [ Journal Credits ](https://www.nature.com/nrclinonc/journal-credits) * [ Editorial input and checks ](https://www.nature.com/nrclinonc/editorial-input-and-checks) * [ Editorial Values Statement ](https://www.nature.com/nrclinonc/editorial-values-statement) * [ Journal Metrics ](https://www.nature.com/nrclinonc/journal-impact) * [ Publishing model ](https://www.nature.com/nrclinonc/publishing-model) * [ Conferences ](https://www.nature.com/nrclinonc/conferences) * [ Web Feeds ](https://www.nature.com/nrclinonc/web-feeds) * [ Contact ](https://www.nature.com/nrclinonc/contact) * [ Publish with us ](javascript:;) ## Publish with us * [ For Authors ](https://www.nature.com/nrclinonc/for-authors) * [ For Referees ](https://www.nature.com/nrclinonc/for-referees) * [Submit manuscript ](https://mts-nrclinonc.nature.com/cgi-bin/main.plex) * [ Subscribe ](https://www.nature.com/nrclinonc/subscribe) * [ Sign up for alerts ](https://journal-alerts.springernature.com/subscribe?journal_id=41571) * [ RSS feed ](https://www.nature.com/nrclinonc.rss) 1. [nature](https://www.nature.com/) 2. [nature reviews clinical oncology](https://www.nature.com/nrclinonc) 3. [news & views](https://www.nature.com/nrclinonc/articles?type=news-and-views) 4. article * News & Views * Published: 31 July 2026 Haematological cancer # More options, more questions in the management of early relapsed and/or refractory multiple myeloma * [Carlyn Rose Tan](https://www.nature.com/articles/s41571-026-01191-6#auth-Carlyn_Rose-Tan-Aff1)[1](https://www.nature.com/articles/s41571-026-01191-6#Aff1) & * [Sham Mailankody](https://www.nature.com/articles/s41571-026-01191-6#auth-Sham-Mailankody-Aff1) [ORCID: orcid.org/0000-0002-2815-9561](https://orcid.org/0000-0002-2815-9561)[1](https://www.nature.com/articles/s41571-026-01191-6#Aff1) [_Nature Reviews Clinical Oncology_](https://www.nature.com/nrclinonc) (2026) [Cite this article](https://www.nature.com/articles/s41571-026-01191-6#citeas) [ Save article ](https://www.nature.com/articles/s41571-026-01191-6/save-research?_csrf=pNQgnmVIU8953qRWVhNQxp67y3LLcazV) [ View saved research ](https://www.nature.com/saved-research) In MonumenTAL-3, the G-protein-coupled receptor class C group 5 memberD-directed bispecific T cell engager talquetamab combined with either daratumumab or daratumumab–pomalidomide conferred significantly longer progression-free survival than daratumumab–pomalidomide–dexamethasone in patients with relapsed and/or refractory multiple myeloma (≥1 prior line of therapy). These results herald a new therapeutic option for such patients but also raise questions regarding how talquetamab-based regimens should be integrated with B cell maturation antigen-directed T cell-redirecting therapies. This is a preview of subscription content, [access via your institution](https://wayf.springernature.com?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41571-026-01191-6) ## Access options [ Access through your institution ](https://wayf.springernature.com?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41571-026-01191-6) Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription 27,99 € / 30 days cancel any time [Learn more](https://shop.nature.com/products/plus/?region=ROW) Subscribe to this journal Receive 12 print issues and online access 176,64 € per year only 14,72 € per issue [Learn more](https://www.nature.com/nrclinonc/subscribe) Rent or buy this article Prices vary by article type from$1.95 to$39.95 [Learn more](https://www.nature.com/articles/s41571-026-01191-6.epdf?no_publisher_access=1&r3_referer=nature) Prices may be subject to local taxes which are calculated during checkout ### Additional access options: * [Log in](https://idp.nature.com/authorize/natureuser?client_id=grover&redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41571-026-01191-6) * [Learn about institutional subscriptions](https://www.springernature.com/gp/librarians/licensing/license-options) * [Read our FAQs](https://support.nature.com/en/support/home) * [Contact customer support](https://www.springernature.com/gp/contact) ## References 1. Hungria, V. et al. Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma. _N. Engl. J. Med._ **391** , 393–407 (2024). [Article](https://doi.org/10.1056%2FNEJMoa2405090) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB2cXhvVaiurrN) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=38828933) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Belantamab%20mafodotin%2C%20bortezomib%2C%20and%20dexamethasone%20for%20multiple%20myeloma&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa2405090&volume=391&pages=393-407&publication_year=2024&author=Hungria%2CV) 2. Dimopoulos, M. A. et al. Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma. _N. Engl. J. Med._ **391** , 408–421 (2024). [Article](https://doi.org/10.1056%2FNEJMoa2403407) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB2cXhvVaiurrI) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=38828951) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Belantamab%20mafodotin%2C%20pomalidomide%2C%20and%20dexamethasone%20in%20multiple%20myeloma&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa2403407&volume=391&pages=408-421&publication_year=2024&author=Dimopoulos%2CMA) 3. San-Miguel, J. et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. _N. Engl. J. Med._ **389** , 335–347 (2023). [Article](https://doi.org/10.1056%2FNEJMoa2303379) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3sXhs1Kgt7jL) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=37272512) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Cilta-cel%20or%20standard%20care%20in%20lenalidomide-refractory%20multiple%20myeloma&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa2303379&volume=389&pages=335-347&publication_year=2023&author=San-Miguel%2CJ) 4. Costa, L. J. et al. Teclistamab plus daratumumab in relapsed or refractory multiple myeloma. _N. Engl. J. Med_. **394** , 739–752 (2025). [Article](https://doi.org/10.1056%2FNEJMoa2514663) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=41363801) [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC13218738) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Teclistamab%20plus%20daratumumab%20in%20relapsed%20or%20refractory%20multiple%20myeloma&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa2514663&volume=394&pages=739-752&publication_year=2025&author=Costa%2CLJ) 5. Rodriguez-Otero, P. et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. _N. Engl. J. Med._ **388** , 1002–1014 (2023). [Article](https://doi.org/10.1056%2FNEJMoa2213614) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3sXmsF2gtbg%3D) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=36762851) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Ide-cel%20or%20standard%20regimens%20in%20relapsed%20and%20refractory%20multiple%20myeloma&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa2213614&volume=388&pages=1002-1014&publication_year=2023&author=Rodriguez-Otero%2CP) 6. Touzeau, C. et al. Teclistamab in multiple myeloma with one to three previous lines of therapy. _N. Engl. J. Med_. (2026). 7. Mina, R. et al. Talquetamab–daratumumab in relapsed or refractory myeloma. _N. Engl. J. Med._ (2026). 8. Chari, A. et al. Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1–2 study. _Lancet Haematol._ **12** , e269–e281 (2025). [Article](https://doi.org/10.1016%2FS2352-3026%2824%2900385-5) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB2MXmt1Okurg%3D) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=40090350) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Safety%20and%20activity%20of%20talquetamab%20in%20patients%20with%20relapsed%20or%20refractory%20multiple%20myeloma%20%28MonumenTAL-1%29%3A%20a%20multicentre%2C%20open-label%2C%20phase%201%E2%80%932%20study&journal=Lancet%20Haematol.&doi=10.1016%2FS2352-3026%2824%2900385-5&volume=12&pages=e269-e281&publication_year=2025&author=Chari%2CA) 9. Mailankody, S. et al. GPRC5D-targeted CAR T cells for myeloma. _N. Engl. J. Med._ **387** , 1196–1206 (2022). [Article](https://doi.org/10.1056%2FNEJMoa2209900) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB38XisF2kt7zO) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=36170501) [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10309537) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=GPRC5D-targeted%20CAR%20T%20cells%20for%20myeloma&journal=N.%C2%A0Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa2209900&volume=387&pages=1196-1206&publication_year=2022&author=Mailankody%2CS) 10. Maura, F. et al. Plasma cell identity escape drives resistance to anti-BCMA T-cell-redirecting therapy in multiple myeloma. Preprint at _bioRxiv_ (2025). [Download references](https://citation-needed.springer.com/v2/references/10.1038/s41571-026-01191-6?format=refman&flavour=references) ## Acknowledgements The work of both authors is supported, in part, by a National Cancer Institute Core Grant (P30 CA008748) to their institution (Memorial Sloan Kettering Cancer Center). S.M. acknowledges support from a Blood Cancer United Scholar in Clinical Research grant. ## Author information ### Authors and Affiliations 1. Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA Carlyn Rose Tan & Sham Mailankody Authors 1. Carlyn Rose Tan [View author publications](https://www.nature.com/search?author=Carlyn%20Rose%20Tan) Search author on:[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Carlyn%20Rose%20Tan)[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Carlyn%20Rose%20Tan%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en) 2. Sham Mailankody [View author publications](https://www.nature.com/search?author=Sham%20Mailankody) Search author on:[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Sham%20Mailankody)[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Sham%20Mailankody%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en) ### Corresponding author Correspondence to Sham Mailankody. ## Ethics declarations ### Competing interests C.R.T. reports research funding from Janssen and Sanofi; personal fees from MJH Life Sciences; and has received honoraria for consultancy and/or participated in the advisory boards for Janssen and Sanofi. S.M. reports research funding from Allogene Therapeutics, Bristol Myers Squibb, Caribou Therapeutics, Fate Therapeutics, Janssen Oncology and Takeda Oncology; has received consulting fees from AbbVie, ArcellX, BioAscend, Bristol Myers Squibb, Cytel, EviCore, HMP Education, Janssen Oncology, Legend Biotech and Optum; and honoraria from MJH Life Sciences, OncLive, Physician Education Resource and Plexus Communications. ## Supplementary information ### [Supplementary information (download PDF )](https://media.springernature.com/original/springer-static/esm/art%3A10.1038%2Fs41571-026-01191-6/MediaObjects/41571_2026_1191_MOESM1_ESM.pdf) ## Rights and permissions [Reprints and permissions](https://s100.copyright.com/AppDispatchServlet?title=More%20options%2C%20more%20questions%20in%20the%20management%20of%20early%20relapsed%20and%2For%20refractory%20multiple%20myeloma&author=Carlyn%20Rose%20Tan%20et%20al&contentID=10.1038%2Fs41571-026-01191-6©right=Springer%20Nature%20Limited&publication=1759-4774&publicationDate=2026-07-31&publisherName=SpringerNature&orderBeanReset=true) ## About this article [![Check for updates. Verify currency and authenticity via CrossMark](https://www.nature.com/articles/s41571-026-01191-6)](https://crossmark.crossref.org/dialog/?doi=10.1038/s41571-026-01191-6) ### Cite this article Tan, C.R., Mailankody, S. More options, more questions in the management of early relapsed and/or refractory multiple myeloma. _Nat Rev Clin Oncol_ (2026). https://doi.org/10.1038/s41571-026-01191-6 [Download citation](https://citation-needed.springer.com/v2/references/10.1038/s41571-026-01191-6?format=refman&flavour=citation) * Published: 31 July 2026 * Version of record: 31 July 2026 * DOI: https://doi.org/10.1038/s41571-026-01191-6 ### Share this article Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy shareable link to clipboard Provided by the Springer Nature SharedIt content-sharing initiative ### Subjects * [Cancer immunotherapy](https://www.nature.com/subjects/cancer-immunotherapy) * [Immunotherapy](https://www.nature.com/subjects/immunotherapy) * [Myeloma](https://www.nature.com/subjects/myeloma) * [Randomized controlled trials](https://www.nature.com/subjects/randomized-controlled-trials) [ Access through your institution ](https://wayf.springernature.com?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41571-026-01191-6) [ Buy or subscribe ](https://www.nature.com/articles/s41571-026-01191-6#access-options) * Sections * References * [References](https://www.nature.com/articles/s41571-026-01191-6#Bib1) * [Acknowledgements](https://www.nature.com/articles/s41571-026-01191-6#Ack1) * [Author information](https://www.nature.com/articles/s41571-026-01191-6#author-information) * [Ethics declarations](https://www.nature.com/articles/s41571-026-01191-6#ethics) * [Supplementary information](https://www.nature.com/articles/s41571-026-01191-6#Sec1) * [Rights and permissions](https://www.nature.com/articles/s41571-026-01191-6#rightslink) * [About this article](https://www.nature.com/articles/s41571-026-01191-6#article-info) Advertisement 1. Hungria, V. et al. Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma. _N. Engl. J. Med._ **391** , 393–407 (2024). [Article](https://doi.org/10.1056%2FNEJMoa2405090) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB2cXhvVaiurrN) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=38828933) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Belantamab%20mafodotin%2C%20bortezomib%2C%20and%20dexamethasone%20for%20multiple%20myeloma&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa2405090&volume=391&pages=393-407&publication_year=2024&author=Hungria%2CV) 2. Dimopoulos, M. A. et al. Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma. _N. Engl. J. Med._ **391** , 408–421 (2024). [Article](https://doi.org/10.1056%2FNEJMoa2403407) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB2cXhvVaiurrI) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=38828951) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Belantamab%20mafodotin%2C%20pomalidomide%2C%20and%20dexamethasone%20in%20multiple%20myeloma&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa2403407&volume=391&pages=408-421&publication_year=2024&author=Dimopoulos%2CMA) 3. San-Miguel, J. et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. _N. Engl. J. Med._ **389** , 335–347 [!CAUTION] > MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations. > Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.